Fresenius lowers conversion price of convertible bonds due 2020

By Marisa Wong

Madison, Wis., May 20 – Fresenius Medical Care & Co. KGaA said it adjusted the conversion price of its €400 million convertible bonds due 2020.

The conversion price was lowered to €73.6354 from €73.6448, increasing the conversion ratio to 1,358.04246 from 1,357.86912. The new conversion price became effective on May 20.

The adjustment is due to a dividend payment of €0.78 per share approved by shareholders on Tuesday.

Fresenius is a Bad Homburg, Germany-based provider of dialysis products and services.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.